Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
SoVarGen General Information
SoVarGen has multiple programs in development with their lead candidate SVG-103 in Phase 2 for Tuberous Sclerosis. The company has several other candidates in preclinical and discovery stages targeting various neurological conditions and brain cancers[2].
Contact Information
Drug Pipeline
SVG-103
Phase 2Key Partnerships
Kazia Therapeutics (licensed paxalisib to SoVarGen for intractable seizures in rare central nervous system diseases)[3]
SoVarGen Funding
No funding data available
To view SoVarGen's complete valuation and funding history, request access »